# U.S. Food and Drug Administration

Type: organization (FDA)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/us-food-and-drug-administration-organization
Canonical HTML page: https://getlegalbrief.com/entity/us-food-and-drug-administration-organization

## Timeline

- **2026-02-23**: Expedited Pathway Formalized — FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
- **2024-05-15**: START Pilot Launch — FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
- **2023-03-01**: CBER Reorganization — The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
- **2017-12-19**: Luxturna Approval — FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.

## Recent coverage (2 stories)

### FDA's Flavored Vape OK Under Legal Fire: 5.2% of Teens Vape
2026-06-28 15:16:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 8

The 2025 National Youth Tobacco Survey reports a record low but persistent 5.2% youth e-cig use, intensifying American Lung Association demands for FDA to reverse its flavored vape authorizations. This regulatory reversal could spawn new administrative law challenges and test the scope of FDA’s tobacco authority, especially given the nearly 90% flavor preference among underage users. Legal experts weigh the viability of forced authorization revocations against public health considerations.
Full story: https://getlegalbrief.com/story/fda-flavored-vape-legal-challenge-2025-youth-survey

### FDA Accelerates Gene Therapy Approvals via New Regulatory Framework
2026-02-23 22:35:23 · Sentiment: Bullish · Impact: 8/10 · Sources: 8

The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
Full story: https://getlegalbrief.com/story/fda-expedited-gene-therapy-pathway

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.